precisionmedicineonline3h
FDA Clears Lion TCR to Begin Phase II Trial of TCR T-Cell Therapy in HBV-Related Liver Cancer
The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.
gastroenterologyadvisor6h
Amezalpat Gets Fast Track Status for Hepatocellular Carcinoma
The FDA has granted Fast Track designation to amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma.
TMCnet8h
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
WOBURN, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...